Department of Ophthalmology, University of Pennsylvania School of Medicine, Scheie Eye Institute, D-603 Richards Building, Philadelphia, PA 19104-6075, USA.
Exp Eye Res. 2013 Sep;114:35-47. doi: 10.1016/j.exer.2013.01.001. Epub 2013 Jan 8.
Despite the high prevalence and public health impact of refractive errors, the mechanisms responsible for ametropias are poorly understood. Much evidence now supports the concept that the retina is central to the mechanism(s) regulating emmetropization and underlying refractive errors. Using a variety of pharmacologic methods and well-defined experimental eye growth models in laboratory animals, many retinal neurotransmitters and neuromodulators have been implicated in this process. Nonetheless, an accepted framework for understanding the molecular and/or cellular pathways that govern postnatal eye development is lacking. Here, we review two extensively studied signaling pathways whose general roles in refractive development are supported by both experimental and clinical data: acetylcholine signaling through muscarinic and/or nicotinic acetylcholine receptors and retinal dopamine pharmacology. The muscarinic acetylcholine receptor antagonist atropine was first studied as an anti-myopia drug some two centuries ago, and much subsequent work has continued to connect muscarinic receptors to eye growth regulation. Recent research implicates a potential role of nicotinic acetylcholine receptors; and the refractive effects in population surveys of passive exposure to cigarette smoke, of which nicotine is a constituent, support clinical relevance. Reviewed here, many puzzling results inhibit formulating a mechanistic framework that explains acetylcholine's role in refractive development. How cholinergic receptor mechanisms might be used to develop acceptable approaches to normalize refractive development remains a challenge. Retinal dopamine signaling not only has a putative role in refractive development, its upregulation by light comprises an important component of the retinal clock network and contributes to the regulation of retinal circadian physiology. During postnatal development, the ocular dimensions undergo circadian and/or diurnal fluctuations in magnitude; these rhythms shift in eyes developing experimental ametropia. Long-standing clinical ideas about myopia in particular have postulated a role for ambient lighting, although molecular or cellular mechanisms for these speculations have remained obscure. Experimental myopia induced by the wearing of a concave spectacle lens alters the retinal expression of a significant proportion of intrinsic circadian clock genes, as well as genes encoding a melatonin receptor and the photopigment melanopsin. Together this evidence suggests a hypothesis that the retinal clock and intrinsic retinal circadian rhythms may be fundamental to the mechanism(s) regulating refractive development, and that disruptions in circadian signals may produce refractive errors. Here we review the potential role of biological rhythms in refractive development. While much future research is needed, this hypothesis could unify many of the disparate clinical and laboratory observations addressing the pathogenesis of refractive errors.
尽管屈光不正的患病率很高,对公众健康也有影响,但导致屈光不正的机制仍知之甚少。现在有大量证据支持视网膜是调节正视化和潜在屈光不正的机制的核心这一概念。使用各种药理学方法和实验室动物中定义明确的实验性眼球生长模型,许多视网膜神经递质和神经调质已被牵连到这一过程中。尽管如此,对于理解控制出生后眼睛发育的分子和/或细胞途径,仍然缺乏一个被广泛接受的框架。在这里,我们回顾了两个经过广泛研究的信号通路,实验和临床数据都支持它们在屈光发育中的一般作用:通过毒蕈碱和/或烟碱型乙酰胆碱受体的乙酰胆碱信号传导和视网膜多巴胺药理学。大约两个世纪前,首次研究了毒蕈碱乙酰胆碱受体拮抗剂阿托品作为一种治疗近视的药物,此后许多后续工作继续将毒蕈碱受体与眼球生长调节联系起来。最近的研究表明烟碱型乙酰胆碱受体可能发挥作用;人群调查中被动接触香烟烟雾(其成分包括尼古丁)的屈光效应支持了其临床相关性。在这里回顾的许多令人费解的结果抑制了形成一种解释乙酰胆碱在屈光发育中作用的机制框架。如何利用胆碱能受体机制来开发可接受的方法来使屈光发育正常化仍然是一个挑战。视网膜多巴胺信号传导不仅在屈光发育中具有假定的作用,而且其通过光的上调构成视网膜时钟网络的重要组成部分,并有助于调节视网膜昼夜生理节律。在出生后发育过程中,眼球尺寸会发生幅度的昼夜波动;这些节律在发育实验性屈光不正的眼睛中发生变化。长期以来,关于近视的临床观点推测环境光照起作用,尽管这些推测的分子或细胞机制仍然不清楚。佩戴凹透镜引起的实验性近视会改变大量内在生物钟基因以及编码褪黑素受体和感光色素黑视蛋白的基因的视网膜表达。所有这些证据表明了一个假设,即视网膜时钟和内在视网膜昼夜节律可能是调节屈光发育的机制的基础,昼夜信号的中断可能会产生屈光不正。在这里,我们回顾了生物节律在屈光发育中的潜在作用。虽然需要进行更多的未来研究,但这一假设可以将许多针对屈光不正发病机制的不同临床和实验室观察结果统一起来。